Jounce Therapeutics Inc (JNCE) Expected to Announce Earnings of -$0.36 Per Share

Wall Street brokerages forecast that Jounce Therapeutics Inc (NASDAQ:JNCE) will report earnings of ($0.36) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.46). Jounce Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 5.9%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 14th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.24) to ($1.01). For the next year, analysts anticipate that the company will report earnings of ($1.30) per share, with EPS estimates ranging from ($2.33) to ($0.25). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.11. The company had revenue of $14.53 million for the quarter, compared to analyst estimates of $12.80 million. Jounce Therapeutics had a negative return on equity of 29.58% and a negative net margin of 59.74%.

A number of analysts recently issued reports on JNCE shares. Cowen reaffirmed a “hold” rating on shares of Jounce Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. lowered their target price on Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a research report on Friday, August 10th. HC Wainwright set a $13.00 target price on Jounce Therapeutics and gave the company a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research report on Tuesday, August 14th. Finally, Raymond James lowered their target price on Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $11.92.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Jounce Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 776,016 shares of the company’s stock worth $5,045,000 after buying an additional 41,945 shares during the last quarter. Man Group plc acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $1,299,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $231,000. Renaissance Technologies LLC acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $1,086,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the period. 82.60% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:JNCE opened at $4.59 on Friday. The stock has a market capitalization of $141.27 million, a P/E ratio of -8.05 and a beta of 5.00. Jounce Therapeutics has a 52-week low of $3.30 and a 52-week high of $29.25.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

See Also: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit